Discounted Cash Flow (DCF) Analysis Levered
Relmada Therapeutics, Inc. (RLMD)
$2.94
-0.21 (-6.67%)
All numbers are in Millions, Currency in USD
Free Cash Flow
Year A/P | 2018 Projected | 2019 Projected | 2020 Projected | 2021 Projected | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected |
Revenue | - | - | - | - | - | - | - | - | - | - |
---|---|---|---|---|---|---|---|---|---|---|
Revenue (%) | ||||||||||
Operating Cash Flow | - | - | - | - | - | - | - | - | - | - |
Operating Cash Flow (%) | ||||||||||
Capital Expenditure | - | - | - | - | - | - | - | - | - | - |
Capital Expenditure (%) | ||||||||||
Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Weighted Average Cost Of Capital
Share price | $ 2.94 |
---|---|
Beta | 0.078 |
Diluted Shares Outstanding | 29.63 |
Cost of Debt | |
Tax Rate | 2.68 |
After-tax Cost of Debt | 4.87% |
Risk-Free Rate | |
Market Risk Premium | |
Cost of Equity | 4.964 |
Total Debt | - |
Total Equity | 87.11 |
Total Capital | 87.11 |
Debt Weighting | 0.00 |
Equity Weighting | 100.00 |
Wacc |
Build Up Free Cash Flow
Year A/P | 2018 Projected | 2019 Projected | 2020 Projected | 2021 Projected | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected |
Revenue | - | - | - | - | - | - | - | - | - | - |
---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow | - | - | - | - | - | - | - | - | - | - |
Capital Expenditure | - | - | - | - | - | - | - | - | - | - |
Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
WACC | ||||||||||
PV LFCF | - | - | - | - | - | - | - | - | - | - |
SUM PV LFCF | - |
Terminal Value
Growth in perpetuity method: | |
---|---|
Long-term growth rate | |
WACC (%) | 4.96 |
Free cash flow (t + 1) | - |
Terminal Value | - |
Present Value of Terminal Value | - |
Intrinsic Value
Enterprise Value | - |
---|---|
Net Debt | -5.40 |
Equity Value | - |
Shares Outstanding | 29.63 |
Equity Value Per Share | - |